ClinicalTrials.gg
Not yet recruitingNCT07809984Updated Oct 22, 2026

Prevention of Oral Mucositis in Adults in With Hematologic Malignancy

An interventional study of Aloe Vera Mouthwash and Standard of Care in Acute Leukemia, Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia, sponsored by Wake Forest University Health Sciences. Not yet recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Wake Forest University Health Sciences · Not applicable, Interventional, and Supportive care

Updated Oct 22, 2026Start date movedGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
206
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this quasiexperimental cohort controlled intervention study is to learn if aloe vera mouthwash works better than usual care in the prevention and treatment of oral mucositis. Researchers will compare aloe vera to usual care. Participants in the intervention group will rinse their mouths with aloe vera 4 x/day for 28 days of their treatment. They will also complete questionnaires about oral health and mucositis.

Read the detailed description

Oral mucositis (OM) is a common and debilitating complication of chemotherapy and radiotherapy among adults with acute leukemia, leading to pain, infection risk, treatment delays, and reduced quality of life. This multi-site, cohort controlled quasi-experimental study will evaluate the effectiveness of a nurse-led aloe vera mouthwash intervention compared with usual oral care in preventing and reducing the incidence and severity of OM among hospitalized oncology patients. Primary outcomes include OM incidence and severity measured by Common Terminology Criteria for Adverse Events (CTCAE), with secondary outcomes of pain, quality of life, and overall health assessed weekly using the Oral Mucositis Weekly Questionnaire (OMWQ).

02

Conditions studied

  • Acute Leukemia
  • Acute Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
  • Oral Mucositis

Keywords

  • acute leukemia
  • supportive care
  • aloe vera
  • symptom management
03

In context

Leukemia, Myeloid, Acute

3,667 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.

This study's planned enrollment of 206 is above the median of 40 across 3,005 interventional studies indexed under Leukemia, Myeloid, Acute.

Browse Leukemia, Myeloid, Acute studies →

Lead sponsor

Wake Forest University Health Sciences is the lead sponsor of 1,351 studies on the registry; 201 are open to participants now.

Of its 332 completed or terminated interventional studies of FDA-regulated products, 251 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Medical diagnosis of acute leukemia and receiving high or low intensity chemotherapy
  • English speaking/reading (without an interpreter)
  • Access to a personal email address to support study participation

Exclusion criteria

Exclusion Criteria:

  • Patients with preexisting mucositis.
  • Allergy to Aloe Vera
  • Transplant patients
  • Cognitively impaired or have a psychiatric condition that would prevent ability to provide
  • Pregnant women
  • Patients with an active eating disorder
  • Patients receiving end of life/hospice care
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
206 participants (estimated)

Study arms

  • Active comparator
    Phase 1 Usual Care

    Participants in the usual care phase will receive standard of care

    Other: Standard of Care

  • Experimental
    Phase 2 Intervention

    Participants in the intervention phase will receive aloe vera

    Dietary Supplement: Aloe Vera Mouthwash

Interventions

  • Dietary supplementAloe Vera Mouthwash

    In addition to standard of care, phase 2 participants will receive the aloe vera mouthwash available for order through supply chain services. Health system pharmacy has approved this as a nonmedication and safe for administration with this patient population and other medications. Each participant will have their own bottle and be instructed to swish and spit 15ml (0.5 ounces) of mouthwash following usual oral care prior to meals and at bedtime (four times per day). Nursing staff assess the participants' oral cavity at least twice a day for mucosal integrity, pain, bleeding, or ulceration. While participants are inpatient, the routine oral assessments and administration of the aloe vera will be tracked via documentation in the electronic health record. If participants are discharged prior to 28 days, oral assessments and aloe vera use will be tracked via self-report by participants on the weekly questionnaire.

  • OtherStandard of Care

    Toothbrushing with a soft or ultra-soft toothbrush and fluoride toothpaste a minimum of twice a day, oral rinsing with water or 0.9% sodium chloride four times daily, and denture care as applicable.

06

What researchers measure

Primary outcomes

  1. Incidence of Oral Mucositis

    Number of participants that develop oral mucositis.

    Time frame: Day 28

Secondary outcomes

  1. Participants with Worsening Grade of Mucositis

    Number of participants with worsening grade of mucositis.

    Time frame: Day 28

  2. Participants with Improving Grade of Mucositis

    Number of participants with improving grade of mucositis.

    Time frame: Day 28

Other outcomes

  1. Oral Mucositis Weekly Questionnaire Score

    The Oral Mucositis Weekly Questionnaire is a patient-reported outcome instrument developed to measure oral mucositis impact on patients' daily life. The questionnaire includes 12 items that are individually assessed including: Global health and Quality of life with 2 items rated on 1-7 scale (higher score better); Mouth and throat soreness when present is measured with 7 items on 0-4 scale and 1 overall measure on 0-10 scale; mouth pain and throat pain are also each measured using 0-10 scale (lower scores better)

    Time frame: Baseline and every 7 days for 28 days

07

Study locations

3 sites
08

References and documents

Publications

  • Epstein JB, Beaumont JL, Gwede CK, Murphy B, Garden AS, Meredith R, Le QT, Brizel D, Isitt J, Cella D. Longitudinal evaluation of the oral mucositis weekly questionnaire-head and neck cancer, a patient-reported outcomes questionnaire. Cancer. 2007 May 1;109(9):1914-22. doi: 10.1002/cncr.22620. PubMed 17377917 ↗
  • Fidan O, Arslan S. Development and Validation of the Oral Mucositis Risk Assessment Scale in Hematology Patients. Semin Oncol Nurs. 2021 Jun;37(3):151159. doi: 10.1016/j.soncn.2021.151159. Epub 2021 May 30. PubMed 34078546 ↗
  • National Cancer Institute. (2017). Common toxicity criteria for adverse events (v. 5). https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf
  • Abdalla-Aslan R, Bonomo P, Keefe D, Blijlevens N, Cao K, Cheung YT, Fregnani ER, Miller R, Raber-Durlacher J, Epstein J, Van Sebille Y, Kauark-Fontes E, Kandwal A, McCurdy-Franks E, Finkelstein J, McCarvell V, Zadik Y, Ottaviani G, Amaral Mendes R, Speksnijder CM, Wardill HR, Bossi P; MASCC Mucositis Study Group. Guidance on mucositis assessment from the MASCC Mucositis Study Group and ISOO: an international Delphi study. EClinicalMedicine. 2024 Jun 6;73:102675. doi: 10.1016/j.eclinm.2024.102675. eCollection 2024 Jul. PubMed 38933098 ↗
  • Steinmann D, Babadag Savas B, Felber S, Joy S, Mertens I, Cramer H, Paul A, Layer M, Klafke N, Stolz R, Heyder U, Neuberger P, Winkler M, Idler C, Heine R, Kaschdailewitsch E, John H, Schmeling B, Zielke T, Horneber M, Witt CM, Voiss P. Nursing Procedures for the Prevention and Treatment of Mucositis Induced by Cancer Therapies: Clinical Practice Guideline Based on an Interdisciplinary Consensus Process and a Systematic Literature Search. Integr Cancer Ther. 2021 Jan-Dec;20:1534735420940412. doi: 10.1177/1534735420940412. PubMed 33467951 ↗
  • Shadish W, Cook T, Campbell D. Quasi-experimental designs that use both control groups and pretests. In: Experimental and Quasi-Experimental Designs.; 2002:161.
  • Gundogdu F, Sayar S. Oncology nursing practices in the management of chemotherapy-related oral mucositis in accordance with evidence-based guidelines: a descriptive and cross-sectional study. Support Care Cancer. 2022 Nov;30(11):9549-9557. doi: 10.1007/s00520-022-07361-3. Epub 2022 Sep 16. PubMed 36109394 ↗
  • Medina Cruz E, Palenzuela Luis N, Rodriguez Novo N, Gonzalez Suarez M, Casas Hernandez R, Novo Munoz MM. Instruments for Evaluating the Nutritional Status of Cancer Patients Undergoing Antineoplastic Treatment: A Scoping Review. Nurs Rep. 2024 May 23;14(2):1312-1323. doi: 10.3390/nursrep14020099. PubMed 38921709 ↗
  • Elad S, Cheng KKF, Lalla RV, Yarom N, Hong C, Logan RM, Bowen J, Gibson R, Saunders DP, Zadik Y, Ariyawardana A, Correa ME, Ranna V, Bossi P; Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020 Oct 1;126(19):4423-4431. doi: 10.1002/cncr.33100. Epub 2020 Jul 28. PubMed 32786044 ↗
  • Brown TJ, Gupta A. Management of Cancer Therapy-Associated Oral Mucositis. JCO Oncol Pract. 2020 Mar;16(3):103-109. doi: 10.1200/JOP.19.00652. Epub 2020 Feb 3. PubMed 32048926 ↗

Individual participant data

Plan to share: No — To protect participants identity, we are not able to share individual participant data

09

Updates

1 registry update since Sep 25, 2026
Start date
Oct 2026→Jan 2027
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Start date Oct 2026→Jan 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07809984
Responsible party
Sponsor
First posted
Sep 9, 2026
Start date
Jan 2027 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Feb 2029 (estimated)
Last update
Oct 22, 2026

Study contacts

Tara Albrecht, PhD, ACNP-BC, ACHPN, RN
Contact
tara.albrecht@aah.org
336.716.9619
Jeanne Hlebichuk, PhD, RN, NE-BC, LSS Black Belt
Contact
Jeanne.hlebichuk@aah.org
336.716.9619
Tara Albrecht, PhD, ACNP-BC, ACHPN, RN
principal investigator · Advocate Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aloe vera

Start the discussion